Drugs / 18F-NaF
18F-NaF
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03619655 | Nov 2019 → Nov 2022 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT03497377 | May 2016 → Apr 2020 | metastatic prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03173924 | Jun 2017 → Feb 2028 expected | metastatic prostate carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-NaF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03173924 ↗ |
| Known as | NaF | “Sodium Fluoride (NaF)-PET/CT imaging” NCT03497377 ↗ |
| Known as | Sodium Fluoride | “Sodium Fluoride (NaF)-PET/CT imaging” NCT03497377 ↗ |
| Modality | Diagnostic / imaging agent | “Sodium Fluoride (NaF)-PET/CT imaging” NCT03497377 ↗ |
| Route | Intravenous | “injected through the IV” NCT03497377 ↗ |